5 Years of FDA Shifts on TRT Explained

[Nelson Vergel]

Over the past five years, the FDA has undertaken a sweeping reassessment of testosterone replacement therapy (TRT) — from formulation approvals that expanded delivery options, to a landmark class-wide labeling overhaul driven by the TRAVERSE trial, to the most significant potential indication expansion in TRT history. The trajectory is clear: the agency has moved from a posture of cardiovascular caution toward evidence-based recalibration, while opening a pathway to treat men with idiopathic hypogonadism for the first time.

Everything Just Changed for Testosterone Therapy

5 Years of FDA Shifts Explained

open.substack.com

 

[Nelson Vergel]

Thread 'FDA Testosterone Regulation: The Complete Guide to Label Changes, Cardiovascular Safety, and the Future of TRT Access'

Jan 18, 2026

FDA Testosterone Regulation: The Complete Guide to Label Changes, Cardiovascular Safety, and the Future of TRT Access
Curated By Nelson Vergel | ExcelMale.com | Updated January 2026
​

Is testosterone replacement therapy finally being recognized for what it is—a legitimate medical treatment rather than a dangerous performance-enhancing drug?

For over a decade, men with documented hypogonadism have faced significant barriers to accessing testosterone therapy due to regulatory warnings that many experts now consider outdated and overstated. In February...

• Nelson Vergel
• Replies: 2
• Forum: Petitions, Press Releases and Position Statements

•